Esophageal lesions associated with diphosphonates

Esophageal lesions associated with diphosphonates

Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and effective in preventing osteoporotic fractures, but they can occasionally cause oesophageal adverse events. We report on seven patients who developed severe oesophagitis or oesophageal ulceration during treatment with b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Tidsskrift for den Norske Lægeforening 2000-08, Vol.120 (20), p.2397
Hauptverfasser: Larsen, K O, Stray, N, Engh, V, Sandnes, D
Format: Artikel
Sprache:nor
Schlagworte:
Aged
Alendronate - adverse effects
Diphosphonates - adverse effects
Esophageal Stenosis - chemically induced
Esophagitis - chemically induced
Esophagoscopy
Esophagus - drug effects
Esophagus - pathology
Etidronic Acid - adverse effects
Female
Humans
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 20
container_start_page 2397
container_title Tidsskrift for den Norske Lægeforening
container_volume 120
creator Larsen, K O
Stray, N
Engh, V
Sandnes, D
description Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and effective in preventing osteoporotic fractures, but they can occasionally cause oesophageal adverse events. We report on seven patients who developed severe oesophagitis or oesophageal ulceration during treatment with bisphosphonates. They were registered at our endoscopy unit during a 31-month period. Six of the patients took alendronate (Fosamax) and one etidronate (Didronate). The oesophageal lesions heal on discontinuation of the bisphosphonate. Institution of gastric acid suppression treatment may enhance the healing process. In order to minimise the risk of serious side-effects, it is important to give detailed instructions regarding medication and to ensure that the instructions are properly understood. The risk of serious complications can be reduced by early recognition of oesophageal symptoms and appropriate intervention.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_11475224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11475224</sourcerecordid><originalsourceid>FETCH-LOGICAL-p544-1924686abe3b00e9b3460af497c57e4a9866adbd63da786568aa7b6eaaa823bb3</originalsourceid><addsrcrecordid>eNo1js1qAjEUhbOo1N9XKPMCA_mbm2RZRFtBcONebsy1Exmd4LWUvr0DrYvD4TuLj_MiJlLqUGsp1VhMmc8DelDhVYyVsq7R2k6EWnFfWvwi7KqOOPdXrpC5P2a8U6p-8r2tUi5tz0Ouw8ZzMTphx7T475nYr1f75We93X1slu_bujTW1ipoCx4wkolSUojGgsSTDe7YOLIYPACmmMAkdB4a8IguAiGi1yZGMxNvf9ryHS-UDuWWL3j7PTyvmwfcVD8t</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Esophageal lesions associated with diphosphonates</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Norart Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Larsen, K O ; Stray, N ; Engh, V ; Sandnes, D</creator><creatorcontrib>Larsen, K O ; Stray, N ; Engh, V ; Sandnes, D</creatorcontrib><description>Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and effective in preventing osteoporotic fractures, but they can occasionally cause oesophageal adverse events. We report on seven patients who developed severe oesophagitis or oesophageal ulceration during treatment with bisphosphonates. They were registered at our endoscopy unit during a 31-month period. Six of the patients took alendronate (Fosamax) and one etidronate (Didronate). The oesophageal lesions heal on discontinuation of the bisphosphonate. Institution of gastric acid suppression treatment may enhance the healing process. In order to minimise the risk of serious side-effects, it is important to give detailed instructions regarding medication and to ensure that the instructions are properly understood. The risk of serious complications can be reduced by early recognition of oesophageal symptoms and appropriate intervention.</description><identifier>ISSN: 0029-2001</identifier><identifier>PMID: 11475224</identifier><language>nor</language><publisher>Norway</publisher><subject>Aged ; Alendronate - adverse effects ; Diphosphonates - adverse effects ; Esophageal Stenosis - chemically induced ; Esophagitis - chemically induced ; Esophagoscopy ; Esophagus - drug effects ; Esophagus - pathology ; Etidronic Acid - adverse effects ; Female ; Humans</subject><ispartof>Tidsskrift for den Norske Lægeforening, 2000-08, Vol.120 (20), p.2397</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11475224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Larsen, K O</creatorcontrib><creatorcontrib>Stray, N</creatorcontrib><creatorcontrib>Engh, V</creatorcontrib><creatorcontrib>Sandnes, D</creatorcontrib><title>Esophageal lesions associated with diphosphonates</title><title>Tidsskrift for den Norske Lægeforening</title><addtitle>Tidsskr Nor Laegeforen</addtitle><description>Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and effective in preventing osteoporotic fractures, but they can occasionally cause oesophageal adverse events. We report on seven patients who developed severe oesophagitis or oesophageal ulceration during treatment with bisphosphonates. They were registered at our endoscopy unit during a 31-month period. Six of the patients took alendronate (Fosamax) and one etidronate (Didronate). The oesophageal lesions heal on discontinuation of the bisphosphonate. Institution of gastric acid suppression treatment may enhance the healing process. In order to minimise the risk of serious side-effects, it is important to give detailed instructions regarding medication and to ensure that the instructions are properly understood. The risk of serious complications can be reduced by early recognition of oesophageal symptoms and appropriate intervention.</description><subject>Aged</subject><subject>Alendronate - adverse effects</subject><subject>Diphosphonates - adverse effects</subject><subject>Esophageal Stenosis - chemically induced</subject><subject>Esophagitis - chemically induced</subject><subject>Esophagoscopy</subject><subject>Esophagus - drug effects</subject><subject>Esophagus - pathology</subject><subject>Etidronic Acid - adverse effects</subject><subject>Female</subject><subject>Humans</subject><issn>0029-2001</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1js1qAjEUhbOo1N9XKPMCA_mbm2RZRFtBcONebsy1Exmd4LWUvr0DrYvD4TuLj_MiJlLqUGsp1VhMmc8DelDhVYyVsq7R2k6EWnFfWvwi7KqOOPdXrpC5P2a8U6p-8r2tUi5tz0Ouw8ZzMTphx7T475nYr1f75We93X1slu_bujTW1ipoCx4wkolSUojGgsSTDe7YOLIYPACmmMAkdB4a8IguAiGi1yZGMxNvf9ryHS-UDuWWL3j7PTyvmwfcVD8t</recordid><startdate>20000830</startdate><enddate>20000830</enddate><creator>Larsen, K O</creator><creator>Stray, N</creator><creator>Engh, V</creator><creator>Sandnes, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20000830</creationdate><title>Esophageal lesions associated with diphosphonates</title><author>Larsen, K O ; Stray, N ; Engh, V ; Sandnes, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p544-1924686abe3b00e9b3460af497c57e4a9866adbd63da786568aa7b6eaaa823bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>nor</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Alendronate - adverse effects</topic><topic>Diphosphonates - adverse effects</topic><topic>Esophageal Stenosis - chemically induced</topic><topic>Esophagitis - chemically induced</topic><topic>Esophagoscopy</topic><topic>Esophagus - drug effects</topic><topic>Esophagus - pathology</topic><topic>Etidronic Acid - adverse effects</topic><topic>Female</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Larsen, K O</creatorcontrib><creatorcontrib>Stray, N</creatorcontrib><creatorcontrib>Engh, V</creatorcontrib><creatorcontrib>Sandnes, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Tidsskrift for den Norske Lægeforening</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Larsen, K O</au><au>Stray, N</au><au>Engh, V</au><au>Sandnes, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Esophageal lesions associated with diphosphonates</atitle><jtitle>Tidsskrift for den Norske Lægeforening</jtitle><addtitle>Tidsskr Nor Laegeforen</addtitle><date>2000-08-30</date><risdate>2000</risdate><volume>120</volume><issue>20</issue><spage>2397</spage><pages>2397-</pages><issn>0029-2001</issn><abstract>Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and effective in preventing osteoporotic fractures, but they can occasionally cause oesophageal adverse events. We report on seven patients who developed severe oesophagitis or oesophageal ulceration during treatment with bisphosphonates. They were registered at our endoscopy unit during a 31-month period. Six of the patients took alendronate (Fosamax) and one etidronate (Didronate). The oesophageal lesions heal on discontinuation of the bisphosphonate. Institution of gastric acid suppression treatment may enhance the healing process. In order to minimise the risk of serious side-effects, it is important to give detailed instructions regarding medication and to ensure that the instructions are properly understood. The risk of serious complications can be reduced by early recognition of oesophageal symptoms and appropriate intervention.</abstract><cop>Norway</cop><pmid>11475224</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0029-2001
ispartof Tidsskrift for den Norske Lægeforening, 2000-08, Vol.120 (20), p.2397
issn 0029-2001
language nor
recordid cdi_pubmed_primary_11475224
source MEDLINE; DOAJ Directory of Open Access Journals; Norart Open Access; EZB-FREE-00999 freely available EZB journals
subjects Aged
Alendronate - adverse effects
Diphosphonates - adverse effects
Esophageal Stenosis - chemically induced
Esophagitis - chemically induced
Esophagoscopy
Esophagus - drug effects
Esophagus - pathology
Etidronic Acid - adverse effects
Female
Humans
title Esophageal lesions associated with diphosphonates
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A05%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Esophageal%20lesions%20associated%20with%20diphosphonates&rft.jtitle=Tidsskrift%20for%20den%20Norske%20L%C3%A6geforening&rft.au=Larsen,%20K%20O&rft.date=2000-08-30&rft.volume=120&rft.issue=20&rft.spage=2397&rft.pages=2397-&rft.issn=0029-2001&rft_id=info:doi/&rft_dat=%3Cpubmed%3E11475224%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11475224&rfr_iscdi=true